Business
TherapeuticsMD Announces Presentations on ANNOVERA™ at the 2019 Annual Meeting of the American Society for Reproductive Medicine
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the presentation of
About this update from Therapeuticsmd, Inc.
[{"type":"text","content":" BOCA RATON, Fla.--(BUSINESS WIRE)--\nTherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the presentation of ANNOVERA™ (segesterone acetate and ethinyl estradiol vaginal system) findings at the annual meeting of the American Society for Reproductive Medicine (ASRM) being held in Philadelphia, PA on October 12-16, 2019.\n\n\n“We are excited to present data on cycle control, bleeding discontinuations, and endometrial histology safety in women who used ANNOVERA for one year to prevent pregnancy,” said Dr. Brian Bernick, Co-founder and Director of TherapeuticsMD. “Additional findings suggest that the use of ANNOVERA for 13 cycles does not adversely affect a woman’s return to fertility.”\n\n\nThe posters and presentations will be made available on the Investors & Media section of the company’s website at www.therapeuticsmd.com.\n\n\n\n\nOral Presentation\n\n\n\n\n\n\n \n\n\n\nDate:\n\n\n\n\nOctober 14, 2019\n\n\n\n\n\nTime:\n\n\n\n\n12:00-12:15 PM\n\n\n\n\n\nTitle:\n\n\n\n\nBleeding Patterns and Endometrial Safety with a 1-Year, Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System (Program ID: O-24)\n\n\n\n\n\n\n\nPoster\n\n\n\n\n\n\n \n\n\n\nDate:\n\n\n\n\nOctober 16, 2019\n\n\n\n\n\nTime:\n\n\n\n\n6:30-7:45 AM\n\n\n\n\n\nTitle:\n\n\n\n\nReturn to Fertility After 1-Year Use of a Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System Use (Poster: P‐502)\n\n\n\n\n\nANNOVERA IMPORTANT SAFETY INFORMATION\n\n\nWARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS\nSee full prescribing information for complete boxed warning.\n\n\n\nFemales over 35 years old who smoke should not use ANNOVERA. \n\n\nCigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive use.\n\n\n\nCONTRAINDICATIONS\n\n\nANNOVERA is contraindicated and should not be used in women with a high risk of arterial or venous thrombotic diseases; current or history of breast cancer or other estrogen- or progestin-sensitive cancer; liver tumors, acute hepatitis, or severe (decompensated) cirrhosis; undiagnosed abnormal uterine bleeding; hypersensitivity to any of the components of ANNOVERA; and use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.\n\n\nWARNINGS AND PRECAUTIONS\n\n\n\nStop ANNOVERA ...